Teva CEO calls it quits

Share this article:

One day after he dismissed rumors of a dispute over cost-saving initiatives and layoffs between him and Teva's chariman as “baseless," CEO Jeremy Levin announced he will step down from the drugmaker.

During a conference call with analysts, the chairman said that “the differences were over nuances rather than disagreement about the strategy itself. It just got to the point where the slight differences couldn't be resolved and we thought it was better to part ways,” reported Bloomberg.

David Moris of BMO Capital Markets called the firm a "very dysfunctional organization" on the same call.

Levin had spent less than 18 months at Teva after joining the company from Bristol-Myers Squibb.

Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Researchers hit links for charity

The PMR Charities Golf Classic teed up more than $20,000 for St. Jude Children's Research Hospital.

FDA to review Neupogen biosimilar

Novartis subsidiary Sandoz announced Thursday that the FDA has agreed to review its filgrastim biosimilar which is already approved in 40 countries.

FDA approves a new painkiller

Targiniq ER combines the prescription opioid oxycodone and naloxone, which is often used to treat overdoses.